Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: Results of a prospective, multicenter, phase II clinical trial

Haematologica

Volumn 99, Issue 7, 2014, Pages

  Briones, Javier ^a   Novelli, Silvana ^a   García Marco, José A ^b   Tomás, José F ^c   Bernal, Teresa ^d   Grande, Carlos ^e   Canales, Miguel A ^f   Torres, Antonio ^g   Moraleda, José M ^h   Panizo, Carlos ⁱ   Jarque, Isidro ^j   Palmero, Francisca ^k   Hernández, Miguel ^l   González Barca, Eva ^m   López, Dulce ^a   Caballero, Dolores ⁿ  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c MD ANDERSON CANCER CENTER   (Spain)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

ⁱ UNIVERSITY CLINIC OF NAVARRA   (Spain)

^j HOSPITAL UNIVERSITARIO LA FE   (Spain)

^k HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^l HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^m Oncology Department   (Spain)

ⁿ HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

more..

Author keywords

Autologous transplantation; Diffuse large B cell lymphoma; Ibritumomab tiuxetan; Relapse

Indexed keywords

IBRITUMOMAB TIUXETAN;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE COURSE; HUMAN; LARGE CELL LYMPHOMA; LETTER; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE;

FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; TRANSPLANTATION CONDITIONING;

EID: 84903575443     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.108308     Document Type: Letter

References (3)

1. Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C, et al. Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica. 2014;99(3):505-10.
2. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-86.
3. Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R, et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer. 2012;118 (19):4706-14.